Rhythm Pharmaceuticals Closes Series A Financing At $40 Million
Rhythm Pharmaceuticals completed its Series A financing at $40 million. The Boston, Mass.-based biotechnology company is developing therapies against metabolic diseases, such as diabetes. The round was led by MPM Capital and New Enterprise Associates. The two first held a first close on the Series A funding at $21 million earlier this year. Third Rock Ventures invested in Rhythm Pharmaceuticals. Lou Tartaglia, a partner at Third Rock, was named to Rhythm Pharmaceuticals’ board.
8 September 2010•3 mins read
